^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    P013 (pertuzumab biosimilar)

    i
    Associations
    News

    Trials

    Company:
    CinnaGen
    Drug class:
    HER2 dimerization inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer (NCT04957212)
    Phase 3
    Cinnagen
    Completed
    Last update posted :
    07/26/2024
    Initiation :
    08/11/2018
    Primary completion :
    05/27/2020
    Completion :
    05/27/2020
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • P013 (pertuzumab biosimilar)